Osteonecrosis of the Jaw in Myeloma Patients Receiving Denosumab or Zoledronic Acid. Comment on Pivotal Trial by Raje et al. Published on Lancet Oncology

The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on in...

Full description

Saved in:
Bibliographic Details
Published in:Dentistry journal 2018-09, Vol.6 (3), p.42
Main Authors: Fusco, Vittorio, Campisi, Giuseppina, de Boissieu, Paul, Monaco, Federico, Baraldi, Anna, Numico, Gianmauro, Bedogni, Alberto
Format: Article
Language:English
Subjects:
Acids
Biocompatibility
Cancer therapies
Comment
denosumab
Drug dosages
Incidence
Jaw
medication-related osteonecrosis of the jaw
Metastasis
Monoclonal antibodies
MRONJ
Multiple myeloma
Myeloma
ONJ
Osteonecrosis
osteonecrosis of the jaw
Patients
Prostate cancer
Surgeons
Targeted cancer therapy
Tomography
Tumors
Zoledronic acid
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The recent randomized trial, published by Raje et al., on Lancet Oncology is potentially practice changing. It proposes that denosumab is a valid alternative to zoledronic acid in the treatment of myeloma patients. However, several points need further data and more details, such as information on incidence, diagnosis, and follow-up of osteonecrosis of the jaw (ONJ) cases, observed among treated patients. Adopted definition to adjudicate ONJ cases, type of registration of potential ONJ cases, length of observation are possible causes of potential underestimation of ONJ incidence in their study. Future updated evaluations with longer follow-up, and including actuarial estimation, are required for final judgment on ONJ risk in myeloma patients receiving denosumab, and comparison with ONJ risk by zoledronic acid.
ISSN:2304-6767
DOI:10.3390/dj6030042